Fulcrum Therapeutics Inc. News
Latest updates and market news for FULC
7 news
Dec 7 - Dec 13, 2025
Page 1
GlobeNewswire
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data
📊
AI Sentiment
Positive
7/10
MT Newswires
Fulcrum Therapeutics Launches $150 Million Common Stock Offering
📊
AI Sentiment
Positive
6/10
GlobeNewswire
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
📊
AI Sentiment
Positive
6/10
MT Newswires
RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk
📊
AI Sentiment
Positive
6/10
MT Newswires
Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell
📊
AI Sentiment
Positive
7/10
Share this news page